Skip to main content Skip to search Skip to main navigation

EC: Position Paper on 'Hybrid Audits'

The European Commission's Medical Device Coordination Group (MDCG) published a definition on ‘hybrid audits’ in early December.

The document gives notified bodies some flexibility regarding the duration of physical presence during audits under the Medical Device Regulation (MDR) and the In Vitro Diagnostic Device Regulation (IVDR).

Due to the global COVID-19 pandemic, travel restrictions and other regulations resulted in the suspension of traditional on-site audits. Instead, information and communication technologies (ICTs) have made so-called ‘hybrid audits’ increasingly common. ICTs are explained in Guideline MDCG-2020-4 and the accompanying Q&A.

To clarify the meaning of the term ‘hybrid audit’, the MDCG agrees on the following definition:

“A ‘hybrid audit’ should be understood as an audit on the premises of the manufacturer or its supplier(s) and/or subcontractor(s) with at least one auditor present on the premises and other members of the audit team participating from elsewhere using information and communication technologies (ICT).“

When establishing audits, notified bodies should allow adequate time to review relevant processes at the premises and clearly document which parts of the conformity assessment must be conducted at the premises and which can be conducted remotely. The MDCG can then decide, based on experience, whether changes are necessary.

In addition, the MDCG has asked the Notified Body Coordination Group (NBCG-Med) to further elaborate on the operational elements that must be performed on the premises of the auditee.


Source:

EC: MDCG-Dokument

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
What are the requirements for gas distribution systems?

What are the requirements for gas distribution systems?

You can view the answer here:
Read more
What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
Previous
Next